Spots Global Cancer Trial Database for Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Official Title: Different Strategies Using Autoantibodies and/or CT Scan Detection of Lung Cancer

Study ID: NCT01700257

Conditions

High Risk of Developing Lung Cancer

Interventions

CT scan & Early CDT Lung test

Study Description

Brief Summary: Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.

Detailed Description: In this trial, the addition of a blood biomarker test is being combined with early LDCT to determine if screening with combination may result in detection of more lung cancer at an earlier stage of disease.The study will also assess if the blood test is able to detect lung cancers in high risk individuals when the LDCT is negative for cancer. There will be health-economic costs included in the final analysis of study data.